Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US7598078: Settings for recombinant adenoviral-based vaccines

Share

Filing Information

Inventor(s) Menzo Jans Havenga · Lennart Holterman · Stefan Kostense · Maria Grazia Pau · Mieke C. Sprangers · Ronald Vogels ·
Assignee(s) Crucell Holland B.V. ·
Attorney/Agent(s) TraskBritt, P.C. ·
Primary Examiner Bo Peng ·
Application Number US11105725
Filing date 04/14/2005
Issue date 10/06/2009
Prior Publication Data
Predicted expiration date 02/10/2025
Patent term adjustment 476
U.S. Classifications 435/320.1  · 424/932  · 435/456  · 435/455  ·
International Classifications C12N1500  · C12N1509  · C12N1563  ·
Kind CodeB2
Related U.S. Application DataCROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of International Patent Application No. PCT/EP03/050748, filed on Oct. 23, 2003, designating the United States of America, and published, in English, as PCT International Publication No. WO 2004/037294 A2 on May 6, 2004, which claims priority under 35 U.S.C. § 119 to International Patent Application No. PCT NL2/00671, filed Oct. 23, 2002, the entirety of both of which are incorporated by this reference.
Foreign Priority WO20PCTNL0200671 - 10/23/2002 ·
5 Claims, 37 Drawings


Abstract

The present invention provides new uses of recombinant adenoviral vectors in vaccination regimens, such as prime/boost set-ups and subsequent vaccinations and applications for gene therapy. Moreover, the invention provides new assays to determine the best regimen for applying the most suitable recombinant viral vector in a vaccination or gene therapy setting.

Independent Claims | See all claims (5)

  1. 1. An improvement in a method of delivering a nucleic acid sequence of interest to a subject using an adenoviral delivery vehicle, the method comprising: administering to the subject a recombinant adenovirus vector of Ad35 serotype having a nucleic acid sequence encoding a malaria antigen; and administering to the subject, subsequent to administering the recombinant adenovirus vector of the Ad35 serotype, a recombinant adenovirus vector of Ad5 serotype having a nucleic acid sequence encoding essentially the same malaria antigen.
  2. 2. A method of delivering a nucleic acid sequence encoding a malaria antigen to a subject, the method comprising: administering a recombinant adenovirus vector of Ad5 serotype to a subject previously administered a recombinant adenovirus vector of Ad35 serotype, wherein the recombinant adenovirus vector of Ad35 serotype and the adenovirus vector of Ad5 serotype each comprise a nucleic acid sequence encoding essentially the same malaria antigen.
  3. 3. A method of delivering a nucleic acid sequence encoding a malaria antigen to a subject, the method comprising: screening a human or animal for the presence of neutralizing antibodies against an adenovirus of Ad35 serotype; and administering a recombinant adenovirus vector of Ad35 serotype encoding a malaria antigen and subsequently with a recombinant adenovirus of Ad5 serotype encoding essentially the same malaria antigen.
  4. 4. A method of delivering a nucleic acid sequence encoding a malaria antigen to a subject, the method comprising: administering a recombinant adenovirus vector of Ad5 serotype to a subject previously administered a recombinant adenovirus vector of Ad35 serotype, wherein the recombinant adenovirus vector of Ad35 serotype and the adenovirus vector of Ad5 serotype each comprise a nucleic acid sequence encoding an identical malaria antigen.
  5. 5. A method of delivering nucleic acid sequences encoding a malaria antigen to a subject, the method comprising: screening a subject for the presence of neutralizing antibodies against an adenovirus of Ad35 serotype; administering to the subject a recombinant adenovirus vector of Ad35 serotype comprising a nucleic acid sequence encoding the malaria antigen; and, subsequent thereto, administering to the subject a recombinant adenovirus of Ad5 serotype comprising a nucleic acid sequence encoding the malaria antigen, so as to deliver the nucleic acid sequences encoding the malaria antigen to a subject.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US5922315 Genetic Therapy, Inc. Roy Jul 1999
US5994128 IntroGene B.V. Fallaux et al. Nov 1999
US6492169 Crucell Holland, B.V. Vogels et al. Dec 2002
US6670188 Crucell Holland B.V. Vogels et al. Dec 2003
US6733993* Merck & Co., Inc. Emini et al. May 2004
US6913922* Crucell Holland B.V. Bout et al. Jul 2005
US20030044421 Emini et al. Mar 2003

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
EP99201545.3May 1999
EP0978566Crucell Holland B.V.Feb 2000
WO199626281Aug 1996
WO199832842Jul 1998
WO199850053Nov 1998
WO199964582INTROGENE B.V.Dec 1999
WO200003029INTROGENE B.V.Jan 2000
WO200052186INTROGENE B.V.Sep 2000
WO200060106MERCK & CO., INC.Oct 2000
WO200070071INTROGENE B.V.Nov 2000
WO200102607MERCK & CO., INC.Jan 2001
WO200121201ISIS INNOVATION LIMITEDMar 2001
WO200222080MERCK & CO., INC.Mar 2002
WO200224730CRUCELL HOLLAND B.V.Mar 2002
WO2002053759Jul 2002
WO2004028478MEDIMMUNE VACCINES, INC.Apr 2004
* cited by examiner

Other Publications

Rodrigues EG et al. “Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria.” J Immunol. Feb 1, 1997;158(3):1268-74.*
Natuk et al. “Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees” AIDS Res. Hum. Retrovirus, 1993, vol. 9, No. 5, pp. 395-404.*
Tetteh K. et al “Progress and challenges towards the development of malaria vaccines.” Biogruds, 2007;21(6):357-73.*
PCT International Search Report, PCT/EP03/50748, dated Sep. 27, 2004.
PCT International Preliminary Examination Report, PCT/EP03/50748, dated Feb. 14, 2005.
Mack et al., “Circumvention of Anti-Adenovirus Neutralizing Immunity by Administration of an Adenoviral Vector of an Alternate Serotype,” Human Gene Therapy, 1997, pp. 99-109, vol. 8, No. I.
Mastrangeli et al., “‘Sero-Switch’ Adenovirus-Mediated in Vivo Gene Transfer: Circumvention of Anti-Adenovirus Humoral Immune Defenses Against Repeat Adenovirus Vector Administration by Changing the Adenovirus Serotype,” Human Gene Therapy, 1996. pp. 79-87, vol. 7, No. 1.
Parks et al., “Use of a helper-dependent adenoviral vectors of alternative serotype permits repeat vector administration,” Gene Therapy, Sep. 1999, pp. 1565-1573, vol. 6, No. I.
Moffatt et al., “Circumvention of Vector-Specific Neutralizing Antibody Response by Alternating Use of Human and Non- Human Adenoviruses: Implications in Gene Therapy,” Virology, Jun. 30, 2000, pp. 159-167, vol. 272, No. 1.
Lubeck et al., “Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus,” Proc. Natl. Acad. Sci. USA, 1989, pp. 6763-6767, vol. 86, No. 17.
Natuk et al., “Immunogenicity of Recombinant Human Adenovims—Human Immunodeficiency Virus Vaccines in Chimpanzees,” AIDS Research and Human Retroviruses, 1993, pp. 395-404, vol. 9, No. 5.
Natuk et al., “Adenovirus—human deficiency virus (HIV) envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model,” Proc. Natl. Acad. Sci. USA, Aug. 1992, pp. 7777-7781, vol. 89, No. 16.
Hsu et al., “Immunogenicity of Recombinant Adenovirus-Respiratory Syncytial Virus Vaccines with Adenvirus Types 4, 5, and 7 Vectors in Dogs and a chimpanzee,” Journal of Infectious Diseases, Oct. 1, 1992, pp. 769-775, vol. 166, No. 4.
Kass-Eisler et al., “Circumventing the immune response to adenovirus-mediated gene therapy,” Gene Therapy, Feb. 1, 1996, pp. 154-162, vol. 2, No. 3.
Natuk et al., “Adenovirus Vectored Vaccines,” Developments in Biological Standardization, 1994, pp. 71-77, vol. 82.
Roy et al., “Circumvention of Immunity to the Adenovirus Major Coat Protein Hexon,” Journal of Virology, Aug. 1998, pp. 6875- 6879, vol. 72, No. 8.
Sullivan et al., “Development of a preventive vaccine for Ebola virus infection in primates,” Nature, 2000, pp. 605-609, vol. 408, No. 6812.
Shiver et al., “Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity,” Nature, 2002, pp. 331-335, vol. 415, No. 6869.
Basler et al., “Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35,” Gene, 1996, pp. 249-254, vol. 170.
Flomenberg et al., “Molecular Epidemiology of Adenovirus Type 35 Infections in lmmunocompromised Hosts,” The Journal of Infectious Diseases, Jun. 1987, pp. 1127-1134, vol. 155, No. 6.
Flomenberg et al., “Sequence and genetic Organization of Adenovirus Type 35 Early Region 3,” Journal of Virology, Nov. 1988, pp. 4431-4437, vol. 62, No. II.
Gahery-Segard et al., “Immune response to recombinant Capsid Proteins of Adenovirus in Humans: Antifiber and Anti- Penton Base Antibodies Have a Synergistic Effect on Neutralizing Activity,” Journal of Virology, Mar. 1998, pp. 2388-2397, vol. 72, No. 3.
Kang et al., “Molecular Cloning and Physical Mapping of the DNA of Human Adenovirus Type 35,” Acta Microbiologica Hungarica, 1999, pp. 67-75, vol. 36, No. l.
Krasnykh et al., “Generation of Recombinant Adenovirus Vectors with modified Fibers for Altering Viral Tropism,” Journal of Virology, Oct. 1996, pp. 6839-3846, vol. 70, No. 10.
Notice of Opposition to a European Patent, Patent No. 1054064, by Cell Genesys Inc., dated Jul. 5, 2005.
Rosenfeld et al., Adenovirus-Mediated Transfer of a recombinant alpha-l-Antitrypsin Gene to the Lung Epithelium in Vivo, Science, Apr. 19, 1991, pp. 431-434, vol. 252.
Stevenson et al., “Human Adenovirus Serotypes 3 and 5 Bind to Two Different Cellular receptors via the Fiber Head Domain,” Journal of Virology, May 1995, pp. 2850-2857, vol. 69, No. 5.
Stratford-Perricaudet et al., “Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector,” Human Gene Therapy, 1990, pp. 241-256, vol. I.
European Search Report, EP 03 78 0172, dated Dec. 6, 2007.
Bostic et al., Quantitative Analysis of Neutralizing Immune Response to Human Parvovirus B19 Using a Novel Reverse Transcriptase-Polymerase Chain Reaction-Based Assay, Journal of Infectious Diseases, 1999, pp. 619-626, vol. 179, Chicago, IL, US.
Klein et al., Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR, Gene Therapy, 2000, pp. 458-463, vol. 7.
Nishimura et al., Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies, Journal of Virology, Mar. 2002, pp. 2123-2130, vol. 76, No. 5.
Schroter et al., Quantitative Detection of Hepatitis C Virus RNA by Light Cycler PCR and Comparison with Two Different PCR Assays, Journal of Clinical Microbiology, Feb. 2001, pp. 765-768, vol. 39, No. 2.
Spenlehauer et al., A Luciferase-Reporter Gene-Expressing T-Cell Line Facilitates Neutralization and Drug-Sensitivity Assays That Use Either R5 or X4 Strains of Human Immunodeficiency Virus Type 1, Virology, 2001, pp. 292-300, vol. 280.
Sprangers et al., Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors, Journal of Clinical Microbiology, Nov. 2003, pp. 5046-5052, vol. 41, No. 11.
Vogels et al., Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity, Journal of Virology. Aug. 2003, pp. 8263-8271, vol. 77, No. 15.
U.S. Appl. No. 11/384,850, filed Mar. 20, 2006, Vogels et al., Packaging Cells for Recombinant Adenovirus.
U.S. Appl. No. 11/450,038, filed Jun. 8, 2006, Pau et al., Production of Vaccines.
U.S. Appl. No. 11/586,316, filed Oct. 25, 2006, Bout et al., Serotypes of Adenovirus and Uses Thereof.
U.S. Appl. No. 11/665,276, filed Apr. 11, 2007, Havenga et al., Improved Adenoviral Vectors and Uses Thereof.
U.S. Appl. No. 11/665,393, filed Apr. 13, 2007, Pau et al., Malaria Prime/Boost Vaccines.
U.S. Appl. No. 11/667,975, filed May 16, 2007, Havenga et al., Multivalent Vaccines Comprising Recombinant Viral Vectors.
U.S. Appl. No. 11/786,409, fled Apr. 11, 2007, Vogels et al., Complementing Cell Lines.
U.S. Appl. No. 11/800,871, filed May 7, 2007, Vogels et al., Means and Methods for the Production of Adenovirus Vectors.
U.S. Appl. No. 11/809,697, filed Jun. 1, 2007, Hateboer et al., Recombinant Protein Production in a Human Cell.
U.S. Appl. No. 11/879,422, filed Jul. 16, 2007, Marzio et al., Production of Viruses, Viral Isolates and Vaccines.
U.S. Appl. No. 11/899,572, filed Sep. 5, 2007, Vogels et al., Stable Adenoviral Vectors and Methods for Propagation Thereof.
U.S. Appl. No. 11/975,396, filed Oct. 18, 2007, Pau et al., Recombinant Viral-Based Malaria Vaccines.
U.S. Appl. No. 11/978,043, filed Oct. 25, 2007, Vogels et al., New Settings for Recombinant Adenoviral-Based Vaccines.
U.S. Appl. No. 11/980,222, filed Oct. 29, 2007, Bout et al., Serotypes of Adenovirus and Uses Thereof.
U.S. Appl. No. 12/225,259, filed Sep. 16, 2008, Barouch et al., Recombinant Adenoviruses Based on Seroytype 26 and 48, and Use Thereof.
U.S. Appl. No. 12/225,673, filed Sep. 26, 2008, Havenga et al., Compositions Comprising a Recombinant Adenovirus and an Adjuvant.
U.S. Appl. No. 12/317,508, filed Dec. 23, 2008, Pau et al., Malaria Prime/Boost Vaccines.
U.S. Appl. No. 12/380,095, filed Feb. 24, 2009, Pau et al., Production of Vaccines.
* cited by examiner

Referenced By

Document NumberAssigneeInventorsIssue/Pub Date
US8097453 Crucell Holland B.V. Maria G. Pau et al. Jan 2012

Patent Family

The current document is not in a family.